Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Grail

GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint

GRAIL (NASDAQ:GRAL) said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses, though the company confirmed that a primary endpoint in its lar

MarketBeat

Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim

Results presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnoses

The Guardian - UK

New blood test ‘offers genuine hope’ it can detect deadly cancers before symptoms appear

The test is ‘feasible at scale’ on the NHS, say researchers

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Galleri blood test ‘feasible at scale’ on NHS, say experts

The NHS-Galleri trial is exploring how well the blood test works within the health service, alongside screening, to pick up cancer cases earlier.

Evening Standard

GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead

GRAIL (NASDAQ:GRAL) said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company’s CFO, at a Bank of America event. Aaron said t

MarketBeat

I was asked if there was an ‘everything’ test for cancer. Despite bold claims, no such thing exists

For oncologists like me, it would be a different world if we could accurately detect cancer before it metastasised and reassure patients that early intervention saved lives

The Guardian - AU

Grail Stock Is Deeply Oversold on Cancer Test Failings. Is There Any Hope Left to Buy the Dip?

Grail stock crashed on Friday after its NHS-Galleri clinical trial failed to meet primary endpoint. Here’s why investors are cautioned against treating GRAL shares as a bargain.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Stocks Shrug Off Tariff Ruling, Weak GDP: Stock Market Today

Market participants had plenty of news to sift through on Friday, including updates on inflation and economic growth and a key court ruling.

Kiplinger

Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025

These three stocks started 2025 small, but graduated to mid-cap territory after +300% gains. See what caused their rise, and what analysts are forecasting.

MarketBeat

How Dak Prescott’s Text Helped a Cowboys Employee Catch Throat Cancer Early

Tad Carper thinks one simple text message from Dak Prescott may have saved his life.

Sports Illustrated

Why GRAIL Stock Could Be Biotech’s Next Big Breakout

Explore insider buying signals, a promising cancer detection biotech, and why the American Dream is still achievable—even in a down market.

MarketBeat

Simple blood test can pick up cancer cases in ‘false positive’ patients – study

The Galleri blood test by Grail can be given annually and looks for the DNA ‘fingerprint’ of more than 50 deadly cancers.

Evening Standard

New blood test can detect more than 50 cancers early

Galleri has been dubbed the holy grail of cancer tests

The Independent UK

‘Holy grail’ blood test for more than 50 cancers delivers ‘exciting’ results

The Galleri test identifies DNA in the bloodstream that has been shed by cancer cells, giving the earliest signs somebody may have the disease.

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

5 Top Tech Disruptors to Watch

Big change catalyzed by top tech disruptors often leads to big growth.

GOBankingRates

13 Surprising Companies Jeff Bezos Bet On

Bezos' venture capital firm has invested in biotech companies seeking to cure cancer, educational tech companies and more. Here's a look at some of his investments.

Barchart

Why Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)

This dip in Illumina’s stock could be an attractive opportunity for long-term growth investors.

MarketBeat

3 Medical Technology Stocks Outperforming in 2025

Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns.

Get all your
news in one place.

100's of premium titles.
One news app.

Cycling Weekly

Canyon launches DT Swiss developed suspension fork with 40mm of travel

The new suspension fork, aimed at gravel riding is the culmination of a 4-year project with DT Swiss

Cycling News

Canyon launches new suspension fork and Grail RIFT gravel bike: One is promising but the other feels a little mismatched

The brand's new suspension fork has been designed in partnership with DT Swiss and will feature on a Grail gravel bike

Kiplinger

5 Momentum Stocks to Buy Now

Amid volatile trade and rising uncertainty, these momentum stocks have shown strong signs of leadership in the first half of 2025.

Barchart

3 Under-the-Radar Stocks that Legendary Investor Bill Miller Thinks Are Cheap

He believes these stocks are trading at compelling valuations and could outperform the broader market.

Cycling News

Canyon Grail CF SLX 8 AXS review: A gravel race bike that can do it all

The Canyon Grail CF SLX is a rapid gravel race bike that can do everything well

MarketBeat

GRAIL: Biotech Stock Targeting $100B Cancer Market

GRAIL is a small biotech stock on the rise big time recently. Its innovative technology gives it the opportunity to capitalize on a massive addressable market.

Cycling Weekly

Canyon Grail CF SL 7 AXS review: a gravel bike of two halves?

The integrated cockpit and aero tubing are somewhat at odds with the Grail's taller stack height

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.